December 16, 2020
1 min watch
Save
VIDEO: Treatment advances in HER2 metastatic breast cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Nancy U. Lin, MD, spoke with Healio about the advances and challenges in the treatment of HER2-positive metastatic breast cancer.
“We’ve made tremendous progress since the development of HER2-based therapies,” Lin, an associate professor at Harvard Medical School and clinical director of the Breast Oncology Center at Dana-Farber Cancer Institute, said in her recap of her presentation from the San Antonio Breast Cancer Symposium.
Published by:
Sources/Disclosures
Collapse
Source:
Lin NU. Abstract ES7. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Disclosures:
Lin reports serving as a consultant with AstraZeneca and receiving grant support from Genentech and Seattle Genetics.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.